After adjusting for baseline risk, even the gross national income per annum ... 07 session he chaired entitled "ST Elevation Myocardial Infarction: The First 24 Hours." Dr. Smith: I'm Dr. Sidney ...

Verve Therapeutics remains a high-reward investment despite setbacks. Click here to find out why VERV stock is a Buy.

Q4 2024 Earnings Call Transcript March 12, 2025 Amarin Corporation plc beats earnings expectations. Reported EPS is $-0.03, ...

Bridging the health gender gap could add up to $4.05 billion in annual incremental GDP for Singapore by 2040. Read more at ...

Operator Welcome to Amarin Corporation's conference call to discuss its fourth-quarter and full-year 2024 business update and ...

DUBLIN and BRIDGEWATER, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), today announced financial results for the fourth quarter of 2024 and provided a review of fourth ...

making them the only FDA approved non-statins to lower LDL cholesterol and reduce the risk of myocardial infarction and coronary revascularization in both primary and secondary prevention patients.

Despite world-class healthcare and a high life expectancy, women in Singapore spend 12% more of their lives in poor health ...

SGLT2 inhibitors vs placebo were associated with reduced heart failure hospitalization among patients with history of myocardial infarction.

In patients with acute heart failure, it is unclear how body mass index affects clinical outcomes following acute myocardial infarction.

In a trial, sotagliflozin use in patients with diabetes and chronic kidney disease (CKD) was associated with lower risk of ischemic cardiovascular outcomes.